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An  anaphylactoid  reaction  to  recombinant  tissue  plasminogen  activator  (rt-PA)  is  an  uncommon  but  fatal 
complication.  A  39-year-old  man  was  admitted  within  1  hour  of  the  onset  of  a  right  hemispheric  stroke.  He  was 
not  taking  any  specific  medication,  including  angiotensin-converting  enzyme  (ACE)  inhibitors.  A  systemic 
anaphylactoid  reaction  developed  immediately  after  rt-PA  infusion.  However,  the  symptoms  were  improved  after 
treatment  with  a  steroid  and  antihistamine.  Subsequent  intra-arterial  thrombolytic  therapy  resulted  in  complete 
recanalization  and  clinical  improvement.  To  our  knowledge,  this  is  the  first  report  of  a  life-threatening  anaphylactoid 
reaction  after  rt-PA  treatment  followed  by  successful  intra-arterial  thrombolytic  therapy  in  a  patient  who  had  not 
taken  an  ACE  inhibitor.
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Intravenous thrombolysis with recombinant tissue 
plasminogen activator (rt-PA) is the only approved 
treatment for use within 3 hours of the onset of 
acute ischemic stroke. In addition to the well-known 
symptomatic intracranial hemorrhage, life-threatening 
orolingual angioedema and anaphylactoid reaction 
have been reported as serious complications in patients 
with rt-PA,
1–6 and these complications have been em-
phasized in current treatment guidelines.
7
In most cases, previous medication with an angio-
tensin-converting enzyme (ACE) inhibitor is known to 
be a preceding factor for the development of orolingual 
angioedema. Here we report on a life-threatening 
anaphylactoid reaction after rt-PA treatment followed 
by successful intra-arterial thrombolysis in a patient 
without a history of ACE inhibitor use.
CASE REPORT
A 39-year-old man was admitted because of a 
sudden weakness on the left side of his body that 
had developed 1 hour before admission. One year 
previously he had experienced a transient ischemic 
attack involving weakness of the right side of his 
body lasting for 5 minutes. He had not taken any 
medication for several months before admission. His 
medical history was negative for diabetes mellitus 
and hypertension. A neurological examination indicated 
that he was alert, but his eyeballs were partially Journal of Clinical Neurology: Vol. 4, No. 1, 2008
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Figure. Sulcal effacement of the right middle cerebral artery (MCA) territory evident on pretreatment CT 
scans (A, B). Infusing 80,000 U of urokinase into the occluded right MCA (C) resulted in complete 
recanalization being evident on the final angiogram (D).
deviated to the right side with left hemianopia and 
probable visual hemineglect. Left-sided hemiparesis 
(MRC grade I) with densely decreased sensation was 
observed. The plantar response was positive on the 
right side. The score on the National Institutes of 
Health Stroke Scale (NIHSS) was 17. His blood 
pressure was 130/90 mmHg and his pulse rate was 
88 beats/minute. Electrocardiography showed atrial 
fibrillation. Complete blood count, serum chemistry, 
and coagulation parameters including the prothrombin 
time and activated partial thromboplastin time were 
normal. Brain CT performed 80 minutes after stroke 
onset revealed loss of the differentiation between gray- 
and white-matter effacement of cerebral sulci (Fig. A, 
B). No other early ischemic changes were evident. 
Intravenous rt-PA was administered 100 minutes after 
stroke onset according to NINDS rt-PA criteria
8 with 
the patient receiving a 5.85 mg bolus over 1 minute 
followed by 52.65 mg over 60 minutes. Fifteen minutes 
after the infusion commenced, the patient presented 
with dyspnea followed by a rapid decrease in oxygen 
saturation of up to 90% and sinus tachycardia, which 
was accompanied by urticaria spreading from the 
lower abdomen to the chest, neck, and upper extremities 
without orolingual angioedema. His blood pressure 
dropped to 90/40 mmHg and his pulse rate increased 
to 110 beats/minute. Stridor and wheezing developed, 
followed by cyanosis, and then the patient descended 
to a stupor. rt-PA infusion was discontinued, and he 
was treated with 100 mg hydrocortisone, 8 mg chlor-
pheniramine, and 50 mg ranitidine, and endotracheal 
intubation was performed. The vital signs normalized 
after 10 minutes, and he became alert after 40 minutes. 
A neurological examination showed improved findings, Park IS, et al. Life-Threatening Anaphylactoid Reaction With Intravenous rt-PA Thrombolysis
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and he eventually returned to a state similar to that 
upon admission.
Following this improvement, we performed intra- 
arterial thrombolysis with urokinase 4 hours after the 
onset of stroke. A conventional angiogram performed 
at the same time revealed an occlusion on the proximal 
portion of the right middle cerebral artery (M1 division). 
The administration of 80,000 U of urokinase at the 
occlusion site intra-arterially resulted in complete 
recanalization (Fig. C, D). The NIHSS score was 
markedly improved from 17 to 9 at 24 hours after 
rt-PA treatment.
DISCUSSION
This is the first reported case of a life-threatening 
anaphylactoid reaction after rt-PA infusion followed 
by successful intra-arterial thrombolysis. Since rt-PA 
was the only substance consumed by the patient that 
could have induced the anaphylactoid reaction, which 
occurred immediately after the rt-PA infusion, we 
consider that rt-PA induced this reaction.
The induction of an anaphylactoid reaction by 
rt-PA has been reported in less than 2% of patients 
treated for acute myocardial infarction.
9  Anaphylactoid 
reactions reportedly occurred in between 0.9%
5 and 
5.1%
3 of acute ischemic stroke patients, most of 
whom had been taking ACE inhibitors. They usually 
presented with orolingual angioedema with or without 
other symptoms such as hemodynamic collapse, urti-
caria, airway obstruction, and shock. rt-PA is an 
endogenous agent consisting of alteplase (a direct 
thrombolytic agent) with phosphoric acid and arginine 
added to adjust the pH and increase solubility. Despite 
the low antigenic potential of serum, specific IgG 
and IgM antibodies have been found in serum within 
days or weeks after administering rt-PA,
10 and IgE 
antibodies were detected in one case of anaphylaxis 
without angioedema.
11
An anaphylactoid reaction is more likely to result 
from direct activation of the complement system by 
plasmin. The activated complement pathway subse-
quently stimulates mast cells and basophils to release 
potent vasoactive substances, such as bradykinins and 
histamine, which can be provoked by ACE inhibitors.
12 
Since we did not measure the immunoglobulin level, 
the exact underlying mechanism remains unclear.
We did not use epinephrine for the medical manage-
ment of the anaphylactoid reaction due to concern 
about possible vasoconstriction of intracranial vessels 
and hemorrhage with a sudden increase in blood 
pressure. After the resolution of symptoms, we con-
tinued with intra-arterial thrombolysis, which resulted 
in complete recanalization. Fortunately, the patient 
did not show adverse effects after administering 
urokinase, instead showing a gradual clinical improve-
ment. Although combined intravenous and intra-arterial 
thrombolysis is not yet approved, selective infusion 
of thrombolytic agents in patients with persisting 
large-artery occlusion can result in early recanalization, 
finally leading to an improved functional outcome. 
Moreover, the safety of intra-arterial thrombolysis after 
full-dose intravenous rt-PA was recently reported.
13 
When a patient develops an anaphylactoid reaction 
after rt-PA and has a persisting large-artery occlusion, 
it might be possible to proceed to intra-arterial throm-
bolysis after resolving the anaphylactoid reaction.
In conclusion, the possibility of a life-threatening 
anaphylactoid reaction after rt-PA treatment should 
be considered despite this being a rare adverse event. 
Even after the occurrence of a life-threatening ana-
phylactoid reaction related to rt-PA infusion, intra- 
arterial urokinase thrombolysis should be considered 
in order to obtain a better outcome. The immediate 
and appropriate management of our patient improved 
the neurological outcome.
One limitation of this study is that we did not 
perform tests for identifying the cause of anaphylaxis. 
However, the clinical presentation was undoubtedly 
indicative of an anaphylactoid reaction, and hence it 
was not necessary to perform detailed testing to reach 
the clinical decision.
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